S
Shanghai Serum Bio-Technology Co Ltd
SSE:688163
Shanghai Serum Bio-Technology Co Ltd
SSE:688163
Price:
38.25
CNY
8.36%
Market Closed
Market Cap:
¥4.1B
Add Note
Add Target
Capture your thoughts and set a target
Decide at what price you'd be comfortable buying and we'll help you stay ready.
Based on
Margin of Safety
0%
10%
20%
30%
40%
50%
Your Price Target
Linked to
current price
· In Buy Zone
Loading
Note attached
Choose the stock you wish to monitor with a price target
Recently Viewed
|
S
|
Shanghai Serum Bio-Technology Co Ltd
SSE:688163
|
CN |
|
Yara International ASA
OTC:YARIY
|
NO |
|
R
|
RoboSense Technology Co Ltd
HKEX:2498
|
CN |
Income Statement
Earnings Waterfall
Shanghai Serum Bio-Technology Co Ltd
Shanghai Serum Bio-Technology Co Ltd
Income Statement
Shanghai Serum Bio-Technology Co Ltd
Shanghai Serum Bio-Technology Co Ltd
Currency: CNY
| Jun-2021 | Sep-2021 | Dec-2021 | Mar-2022 | Jun-2022 | Sep-2022 | Dec-2022 | Mar-2023 | Jun-2023 | Sep-2023 | Dec-2023 | Mar-2024 | Jun-2024 | Sep-2024 | Dec-2024 | Mar-2025 | Jun-2025 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | ||||||||||||||||||
| Interest Expense |
0
|
0
|
1
|
1
|
1
|
1
|
1
|
1
|
1
|
1
|
1
|
1
|
1
|
1
|
0
|
0
|
0
|
|
| Revenue |
281
N/A
|
194
-31%
|
209
+7%
|
211
+1%
|
191
-10%
|
190
0%
|
174
-8%
|
173
-1%
|
190
+10%
|
191
+1%
|
190
0%
|
192
+1%
|
194
+1%
|
197
+1%
|
195
-1%
|
194
0%
|
198
+2%
|
|
| Gross Profit | ||||||||||||||||||
| Cost of Revenue |
(47)
|
(33)
|
(36)
|
(36)
|
(32)
|
(32)
|
(33)
|
(32)
|
(41)
|
(45)
|
(50)
|
(48)
|
(47)
|
(46)
|
(46)
|
(44)
|
(45)
|
|
| Gross Profit |
235
N/A
|
161
-31%
|
172
+7%
|
175
+2%
|
159
-9%
|
158
-1%
|
141
-11%
|
141
+0%
|
149
+5%
|
146
-2%
|
140
-4%
|
145
+3%
|
147
+2%
|
151
+3%
|
149
-1%
|
151
+1%
|
153
+2%
|
|
| Operating Income | ||||||||||||||||||
| Operating Expenses |
(108)
|
(79)
|
(84)
|
(88)
|
(89)
|
(94)
|
(82)
|
(90)
|
(99)
|
(102)
|
(107)
|
(111)
|
(105)
|
(104)
|
(99)
|
(104)
|
(106)
|
|
| Selling, General & Administrative |
(77)
|
(57)
|
(63)
|
(66)
|
(70)
|
(75)
|
(70)
|
(72)
|
(77)
|
(71)
|
(75)
|
(77)
|
(72)
|
(78)
|
(75)
|
(76)
|
(79)
|
|
| Research & Development |
(31)
|
(22)
|
(24)
|
(23)
|
(20)
|
(20)
|
(12)
|
(15)
|
(19)
|
(28)
|
(27)
|
(33)
|
(34)
|
(24)
|
(20)
|
(21)
|
(20)
|
|
| Depreciation & Amortization |
0
|
(2)
|
(4)
|
0
|
0
|
0
|
(5)
|
0
|
0
|
0
|
(5)
|
0
|
0
|
0
|
(8)
|
0
|
0
|
|
| Other Operating Expenses |
1
|
2
|
7
|
2
|
1
|
2
|
5
|
(2)
|
(3)
|
(3)
|
0
|
(1)
|
1
|
(1)
|
4
|
(8)
|
(8)
|
|
| Operating Income |
127
N/A
|
82
-35%
|
88
+7%
|
88
-1%
|
70
-20%
|
64
-9%
|
58
-9%
|
51
-13%
|
50
-2%
|
44
-11%
|
33
-25%
|
33
+0%
|
42
+27%
|
47
+12%
|
50
+5%
|
47
-5%
|
47
0%
|
|
| Pre-Tax Income | ||||||||||||||||||
| Interest Income Expense |
(7)
|
(1)
|
(0)
|
1
|
8
|
14
|
19
|
23
|
20
|
16
|
13
|
11
|
10
|
13
|
7
|
7
|
6
|
|
| Non-Reccuring Items |
0
|
0
|
0
|
0
|
0
|
0
|
(2)
|
0
|
0
|
0
|
0
|
0
|
0
|
1
|
(5)
|
0
|
0
|
|
| Gain/Loss on Disposition of Assets |
0
|
0
|
(0)
|
0
|
0
|
0
|
(0)
|
0
|
0
|
0
|
(0)
|
0
|
0
|
0
|
(1)
|
0
|
0
|
|
| Total Other Income |
(1)
|
(1)
|
(0)
|
(0)
|
(0)
|
(0)
|
(1)
|
0
|
(1)
|
(0)
|
(1)
|
(1)
|
(1)
|
(1)
|
(0)
|
(1)
|
(1)
|
|
| Pre-Tax Income |
119
N/A
|
81
-32%
|
88
+9%
|
88
+1%
|
79
-11%
|
78
-1%
|
74
-5%
|
73
-1%
|
69
-6%
|
60
-14%
|
45
-24%
|
44
-4%
|
52
+19%
|
60
+16%
|
51
-16%
|
53
+4%
|
51
-3%
|
|
| Net Income | ||||||||||||||||||
| Tax Provision |
(17)
|
(11)
|
(11)
|
(11)
|
(11)
|
(11)
|
(10)
|
(10)
|
(8)
|
(7)
|
(7)
|
(6)
|
(8)
|
(9)
|
(6)
|
(6)
|
(6)
|
|
| Income from Continuing Operations |
102
|
70
|
76
|
77
|
68
|
67
|
64
|
63
|
61
|
52
|
39
|
37
|
44
|
51
|
44
|
47
|
45
|
|
| Net Income (Common) |
102
N/A
|
70
-32%
|
76
+10%
|
77
+1%
|
68
-12%
|
67
-1%
|
64
-4%
|
63
-1%
|
61
-4%
|
52
-14%
|
39
-26%
|
37
-4%
|
44
+19%
|
51
+15%
|
44
-13%
|
47
+5%
|
45
-3%
|
|
| EPS (Diluted) |
0.94
N/A
|
0.64
-32%
|
0.71
+11%
|
0.58
-18%
|
0.62
+7%
|
0.61
-2%
|
0.59
-3%
|
0.58
-2%
|
0.56
-3%
|
0.48
-14%
|
0.36
-25%
|
0.34
-6%
|
0.41
+21%
|
0.47
+15%
|
0.41
-13%
|
0.43
+5%
|
0.42
-2%
|
|
Switch to:
Switch to:
See Also
Discover More
